Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times
10-Q: Quarterly report
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track -- Dermata continues discussions with potential botulinum toxin partners for DMT410 -- Receive
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
Dermata to Present at the Emerging Growth Conference on April 3, 2024
- Dermata to provide a corporate update followed by a live question and answer session -SAN DIEGO, CA / ACCESSWIRE / March 27, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
Dermata to Present at the Emerging Growth Conference on February 7, 2024
- Company to provide a corporate overview followed by a live question and answer session -SAN DIEGO, CA / ACCESSWIRE / February 1, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Derma
Why Dermata Therapeutics Stock Took Off After-Hours
Dermata Therapeutics, Inc. (NASDAQ:DRMAW) shares are trading higher in Thursday's after-hours session after the company announced the issuance of a new patent in Japan for its DMT410 program for the
Dermata Expands Global Intellectual Patent Portfolio With Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment o
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023...
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 -- Received positive feedback from FDA on its End of Phase 2 meeting package in June 2023 -- Completed
Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial
- Dermata is prepared to initiate DMT310 Phase 3 STAR-1 clinical trial by the end of 2023 -- Investigational sites have been selected -- Clinical trial materials are ready to be shipped to investigati
Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 -- Received positive feedback on its End of Phase 2 meeting package from FDA in June 2023 -- Phase 3 ST
Dermata Therapeutics Announces Positive Feedback From FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne
- FDA established key elements of the DMT310 Phase 3 clinical program and delineated a potential regulatory pathway for approval of DMT310 --The DMT310 Phase 3 program will consist of two pivotal tria
Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
SAN DIEGO, CA / ACCESSWIRE / June 13, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical a
Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results
- DMT310 once-weekly topical treatment demonstrated statistically significant improvements at all time points in the three primary endpoints, inflammatory lesion count, noninflammatory lesion count, a
Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / May 26, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical a
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq RulesSAN DIEGO, CA / ACCESSWIRE / May 24, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq
No Data